DESTINY-Gastric03: Analyzing Trastuzumab Deruxtecan for Gastric and GEJ Cancers

At the ESMO Congress 2024, Yelena Janjigian, MD, of Memorial Sloan Kettering Cancer Center, shares an overview of the DESTINY-Gastric03 study and the history of trastuzumab deruxtecan (T-Dxd) for gastric and GEJ cancers.

She addresses how T-Dxd monotherapy compares to its use with fluoropyrimidine and pembrolizumab, the next steps for researching this treatment and whether more testing is warranted before it can be considered a standard of care, and whether it can be used in HER2-negative patients.